{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=secukinumab+300+mg+Q4W",
    "query": {
      "intervention": "secukinumab 300 mg Q4W"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 7,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-28T19:26:27.498Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03504852",
      "title": "Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Moderate to Severe Chronic Plaque-type Psoriasis"
      ],
      "interventions": [
        {
          "name": "secukinumab 150 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 331,
      "start_date": "2018-06-25",
      "completion_date": "2020-07-15",
      "has_results": true,
      "last_update_posted_date": "2021-10-11",
      "last_synced_at": "2026-09-28T19:26:27.498Z",
      "location_count": 38,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 34 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03504852"
    },
    {
      "nct_id": "NCT04300296",
      "title": "PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris"
      ],
      "interventions": [
        {
          "name": "secukinumab 300 mg Q4W",
          "type": "DRUG"
        },
        {
          "name": "secukinumab 300 mg Q2W",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 111,
      "start_date": "2020-07-27",
      "completion_date": "2022-05-03",
      "has_results": true,
      "last_update_posted_date": "2023-08-22",
      "last_synced_at": "2026-09-28T19:26:27.498Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Thousand Oaks, California • Cromwell, Connecticut + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Thousand Oaks",
          "state": "California"
        },
        {
          "city": "Cromwell",
          "state": "Connecticut"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04300296"
    },
    {
      "nct_id": "NCT04638647",
      "title": "Secukinumab Open Label Roll-over Extension Protocol",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Autoimmunity, Inflammation"
      ],
      "interventions": [
        {
          "name": "Secukinumab s.c. injection",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "6 Years to 100 Years"
      },
      "enrollment_count": 1000,
      "start_date": "2020-12-22",
      "completion_date": "2030-04-04",
      "has_results": false,
      "last_update_posted_date": "2026-09-28",
      "last_synced_at": "2026-09-28T19:26:27.498Z",
      "location_count": 28,
      "location_summary": "Fullerton, California • La Mesa, California • San Leandro, California + 25 more",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "San Leandro",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04638647"
    },
    {
      "nct_id": "NCT02008916",
      "title": "16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Spondylitis, Ankylosing"
      ],
      "interventions": [
        {
          "name": "Secukinumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo secukinumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 226,
      "start_date": "2014-01-14",
      "completion_date": "2017-12-11",
      "has_results": true,
      "last_update_posted_date": "2019-01-08",
      "last_synced_at": "2026-09-28T19:26:27.498Z",
      "location_count": 14,
      "location_summary": "Mobile, Alabama • Mesa, Arizona • Peoria, Arizona + 11 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Upland",
          "state": "California"
        },
        {
          "city": "Palm Harbor",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02008916"
    },
    {
      "nct_id": "NCT03478787",
      "title": "Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "risankizumab",
          "type": "DRUG"
        },
        {
          "name": "secukinumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": null,
        "summary": "18 Years and older"
      },
      "enrollment_count": 327,
      "start_date": "2018-05-08",
      "completion_date": "2020-07-08",
      "has_results": true,
      "last_update_posted_date": "2021-07-13",
      "last_synced_at": "2026-09-28T19:26:27.498Z",
      "location_count": 28,
      "location_summary": "Glendale, Arizona • Phoenix, Arizona • Bakersfield, California + 24 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03478787"
    },
    {
      "nct_id": "NCT06331312",
      "title": "Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Polymyalgia Rheumatica"
      ],
      "interventions": [
        {
          "name": "Secukinumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "50 Years to 100 Years"
      },
      "enrollment_count": 162,
      "start_date": "2024-06-28",
      "completion_date": "2028-05-08",
      "has_results": false,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-09-28T19:26:27.498Z",
      "location_count": 13,
      "location_summary": "Avondale, Arizona • Peoria, Arizona • Westlake Village, California + 9 more",
      "locations": [
        {
          "city": "Avondale",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Westlake Village",
          "state": "California"
        },
        {
          "city": "Woodland Hills",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06331312"
    },
    {
      "nct_id": "NCT03099980",
      "title": "Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurativa",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Hidradenitis Suppurativa"
      ],
      "interventions": [
        {
          "name": "secukinumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Tufts Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2016-07-11",
      "completion_date": "2019-01",
      "has_results": false,
      "last_update_posted_date": "2019-06-03",
      "last_synced_at": "2026-09-28T19:26:27.498Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03099980"
    }
  ]
}